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RESEARCH
Cost effectiveness of home ultraviolet B phototherapy for
psoriasis: economic evaluation of a randomised controlled
trial (PLUTO study)
Mayke B G Koek, epidemiologist, medical doctor,1 Vigfu´s Sigurdsson, dermatologist,1 Huib van Weelden,
investigator photodermatology,1 Paul H A Steegmans, dermatologist,2 Carla A F M Bruijnzeel-Koomen,
professor of dermatology/allergology,1 Erik Buskens, professor of medical technology assessment3,4
ABSTRACT
Objective To assess the costs and cost effectiveness of
phototherapy with ultraviolet B light provided at home
compared with outpatient ultraviolet B phototherapy for
psoriasis.
Design Cost utility, cost effectiveness, and cost
minimisation analyses performed alongside a pragmatic
randomised clinical trial (the PLUTO study) at the end of
phototherapy (mean 17.6weeks) and at one year after the
end of phototherapy (mean 68.4 weeks).
Setting Secondary care, provided by a dermatologist in
the Netherlands.
Participants 196 adults with psoriasis who were clinically
eligible for narrowband (TL-01) ultraviolet B phototherapy
were recruited from the dermatology departments of 14
hospitals and were followed until the end of
phototherapy. From the end of phototherapy onwards,
follow-up was continued for an unselected, consecutive
group of 105 patients for one year after end of
phototherapy.
Interventions Ultraviolet B phototherapy provided at
home (intervention) and conventional outpatient
ultraviolet B phototherapy (control) in a setting reflecting
routine practice in the Netherlands. Both treatments used
narrowband ultraviolet B lamps (TL-01).
Main outcome measures Total costs to society, quality
adjusted life years (QALYs) as calculated using utilities
measured by the EQ-5D questionnaire, and the number of
days with a relevant treatment effect (≥50% improvement
of the baseline self administered psoriasis area and
severity index (SAPASI)).
Results Home phototherapy is at least as effective and
safe as outpatient phototherapy, therefore allowing cost
minimisation analyses (simply comparing costs). The
average total costs by the end of phototherapy were €800
for home treatment and €752 for outpatient treatment,
showing an incremental cost per patient of €48 (95% CI
€−77 to €174). The average total costs by one year after
the end of phototherapy were €1272 and €1148
respectively (difference €124, 95% CI €−155 to €403).
Cost utility analyses revealed that patients experienced
equal health benefits—that is, a gain of 0.296 versus
0.291 QALY (home v outpatient) by the end of
phototherapy (difference 0.0052, −0.0244 to 0.0348)
and 1.153 versus 1.126 QALY by one year after the end of
phototherapy (difference 0.0267, −0.024 to 0.078).
Incremental costs per QALY gained were €9276 and
€4646 respectively, both amounts well below the
normally accepted standard of €20000 per QALY. Cost
effectiveness analyses indicated that themean number of
dayswith a relevant treatment effectwas 42.4 versus55.3
by the end of phototherapy (difference −12.9, −23.4 to
−2.4). By one year after the end of phototherapy the
number of days with a relevant treatment effect were
216.5 and 210.4 respectively (6.1, −41.1 to 53.2),
yielding an incremental cost of €20 per additional day
with a relevant treatment effect.
Conclusions Home ultraviolet B phototherapy for
psoriasis is not more expensive than phototherapy in an
outpatient setting and proved to be cost effective. As both
treatments are at least equally effective and patients
express a preference for home treatment, the authors
conclude that home phototherapy should be the primary
treatment option for patients who are eligible for
phototherapy with ultraviolet B light.
Trial registration Current Controlled Trials
ISRCTN83025173 and Clinicaltrials.gov NCT00150930
INTRODUCTION
Psoriasis is a chronic recurrent skin disorder that can be
treated symptomatically in several ways. A highly effec-
tive treatment for psoriasis is phototherapy with ultra-
violet B light,1-4 which is indicated when topical
treatment becomes insufficient. In general, guidelines
and consensus agree that ultraviolet B phototherapy is
the primary treatment option after failure of topical
therapies. After that, treatment with a psoralen and
ultraviolet A (PUVA) or systemic drugs may be consid-
ered, finally followed by so called biological agents.5-7
Phototherapy with ultraviolet B is generally offered
in an outpatient clinic, requiring patients to travel to
the outpatient department during working hours two
or three times a week. This makes it a relatively time
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staff, imposing a substantial burden on patients and,
presumably, on society. Another drawback may be
the limited availability of outpatient phototherapy
units in sparsely populated areas. As a result, patients
living far from an outpatient phototherapy unit may
often receive new and expensive biological treatments
just because the infrastructure to deliver a well estab-
lished and cheaper ultraviolet B phototherapy is
lacking.8
To overcome the drawbacks of phototherapy in the
outpatient clinic, equipment for use at home was intro-
duced in the late 1970s.9-12 Ever since, however, the
safety, effectiveness, and costs of home phototherapy
have been a subject of debate because of the lack of
(randomised) clinical research on the topic. In general,
alleged inferior quality, higher risks, and more
costs11-19 have resulted in few dermatologists embra-
cing home phototherapy.
Recently we provided evidence that home ultraviolet
B treatment for psoriasis is at least equally safe and effec-
tive as the conventional outpatient phototherapy.20 We
also showed that home phototherapy is associatedwith a
lower burden of treatment and is better appreciated by
patients than outpatient phototherapy.20 To date, a fac-
tual cost effectiveness analysis balancing the costs and
effects of either treatment is still lacking. The results of
such a cost effectiveness analysis would be of importance
especially for policymakers and health care insurers.
Since effectiveness and safety of home phototherapy
are not inferior to those of outpatient phototherapy, the
costs of the two treatments become more important in
determining the treatment of choice. Also, in countries
where home phototherapy is unavailable, the results of a
cost effectiveness analysis may aid in the decision to
implement this service.
We therefore carried out an economic evaluation
alongside a randomised controlled trial to investigate
the costs, cost effectiveness, and cost utility of home
based ultraviolet B phototherapy for adults with psor-
iasis compared with conventional outpatient ultravio-
let B phototherapy. The study was performed in a
setting reflecting routine daily practice in the Nether-
lands. We used the societal perspective, and the focus
was on narrowband ultraviolet B treatment for psoria-
sis (TL-01 lamps). The Dutch acronym for this trial is




Full details of the study design and interventions have
been described in our paper presenting the clinical
results of the PLUTO trial,20 in the study protocol
(open access on www.biomedcentral.com/content/
pdf/1471-2288-6-39.pdf),21 and in the web extra on
bmj.com.
The trial was a pragmatic, multicentre, single
blinded, randomised clinical trial. Consenting patients
≥18 years oldwith psoriasis whowere considered clini-
cally eligible for narrowband (TL-01) ultraviolet B
phototherapy were included and randomised to
receive this treatment either at home or in the outpati-
ent department.20 21 In accordance with the pragmatic
design, patient selection and administration of the
interventions in our trial reflected routine practice. As
such, patients randomised to outpatient phototherapy
received treatment in their local hospital andwere trea-
ted two or three times a week. Patients randomised to
receive home phototherapy were temporarily (for the
duration of the phototherapy) provided with a TL-01
home phototherapy unit (Waldmann 100,Waldmann,
Villingen-Schwenningen, Germany) in their homes.
The unit was rented out by home care organisations
(independent suppliers of medical equipment, inclu-
sive of support from specialist nurses), who also deliv-
ered the units at the patients’ homes. Irradiation took
place three to four times a week (every other day),
sometimes starting with daily irradiations. In both
treatment arms the irradiation scheduleswere the sche-
dules normally used by the hospitals and home care
organisations. Neither equipment nor schedules were
modified for the trial. To avoid interferingwith routine
practice, adjuvant use of topical therapywas allowed as
well as all treatment changes initiated after inclusion
and randomisation.
The within-trial economic evaluation was underta-
ken from the societal perspective. It focused on costs
and effects at the end of phototherapy (mean duration
17.6weeks), although results at 12months after the end
of phototherapy are also reported (mean duration
68.4 weeks). At both points in time the two treatments
were compared for their total costs (cost minimisation
analysis, CMA). In addition, a cost utility analysis
(CUA) and cost effectiveness analysis (CEA) were per-
formed: both groups were analysed for their differ-
ences in total costs compared with differences in
quality adjusted life years (QALYs) (cost utility), and
with differences in the number of days with a relevant
treatment effect (cost effectiveness). QALYs were cal-
culated from the EQ-5D quality of life questionnaire,
and a relevant treatment effect was defined as a ≥50%
improvement in the baseline psoriasis severity as mea-
sured with the self administered psoriasis area and
severity index.
Fig 1 schematically represents the plannedmeasure-
ments. The first four measurements (t=0 to t=3) were
planned according to individual clinical landmarks—
that is, coinciding with inclusion in the study, start of
phototherapy, around the 23rd irradiation, and at the
end of phototherapy. When treatments exceeded 46
irradiations we defined 46 irradiations as the end of
phototherapy. For the clinical study, all 196 partici-
pants were followed until the end of phototherapy.
For the economic evaluation, however, a sample of
100 participants was deemed sufficient. As such, from
the end of phototherapy onwards (t=4 to t=9) an unse-
lected group of (the first) 105 consecutive participants
was followed bimonthly for one year. Therefore, ana-
lyses at 12 months after the end of phototherapy are
based on data of 105 participants.
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Resource use
We collected data on the use of resources at the level of
individual participants. Several methods were used to
collect data (see fig 1). Using a diary, patients recorded
the frequency and duration of their irradiations as well
as the frequency of visits paid to the dermatologist or
general practitioner until the end of the phototherapy
(t=3). During the follow-up (t=4 to t=9), we recorded
frequency of visits to dermatologist and general practi-
tioner with a bimonthly questionnaire. Occurrence
and duration of a newly started phototherapy during
follow-up were monitored with the bimonthly ques-
tionnaire as well. At baseline we applied a question-
naire to collect details on travel distances, travel time,
means of travelling to the dermatology outpatient
department and general practice, and parking costs.
Concomitant use of drugs for psoriasis (topical and sys-
temic drugs) was retrieved retrospectively from the
patients’ pharmacists. We recorded patients’ absence
from work and reduced productivity while at work
until the end of treatment using the health and labour
questionnaire.22
Costs
Table 1 shows the various resources and their unit
costs. Except for the treatment costs of home photo-
therapy, all costs were assessed from the societal per-
spective and were calculated per patient by
multiplying the volume of resource use by the unit
costs.Using themanual for costing of theDutchhealth-
care insurance board (CVZ),23 we assessed all costs in
Euros (€) and based them on the 2003 price level or
adjusted them accordingly using national indices. 24
As stated above, the treatment costs of home photo-
therapywere not calculated froma societal perspective
—because the home care organisations were reluctant
to submit commercially sensitive information on pri-
cing. As a result, we had to base the treatment costs of
home phototherapy on the invoice tariffs of the two
home care organisations (presented in web extra on
bmj.com). It should be noted that the invoice tariffs
may be higher than the true societal costs of home
phototherapy. Unit costs of ultraviolet B phototherapy
in anoutpatient department (costs per irradiation)were
calculated from the societal perpective and included
the costs of staff, equipment, maintenance, deprecia-
tion, accommodation, and overheads (see web extra).
Differences in treatment costs between general hospi-
tals and university hospitals were accounted for by cal-
culating weighted mean costs per irradiation based on
the number of irradiations in both types of hospitals.
Consultation costs of dermatologists were based on
themanual for costing.23 Also here, differences in costs
between general hospitals and university hospitals
were accounted for by calculating weighted mean
costs per consultation based on the number of consul-
tations in both type of hospitals.
Consultation costs for general practitioners were the
costs presented in the manual for costing.23 Costs of
concomitant drugs were determined from trial data
using the prices in the Dutch medication guide
2003,25 and to these we added a pharmacist’s fee of
€6.30.26 Travel costs were calculated from travel dis-
tances at a price of €0.16 per km. Parking costs were
€2.50 per visit to outpatient departments23 and €0.25
per visit to general practices (the latter estimated from
trial data).
We planned to calculate all costs of lost productivity
(absence from work and reduced productivity while at
work) by applying mean hourly productivity costs
varying with age and sex.23 The data obtained with
the health and labour questionnaire,22 however,
seemed unrepresentative of absence due to photother-
apy for psoriasis. Moreover, additional trial data and
previous studies led us to conclude that short term
absence is often compensated for during normal work-
ing hours.27 28We therefore considered the costs due to
short term absence from paid and unpaid work to be
negligible (for further explanation, see web extra). To
calculate productivity costs from lost productivity
while at work, we used an elasticity of 0.8, meaning a
loss of 10 hours at work causes only 8 hours of produc-
tivity losses.23
Up to the end of phototherapy (t=3), complete cost
data were available for 88% (173/196) of the partici-
pants. Missing values were imputed with the group
mean for that particular cost item.
Up to one year follow-up after the end of photother-
apy (t=9), complete data on costs of treatment, consul-
tations, medication, travelling, and parking were
available for 88-100% (92-105) of the 105 participants.













































































































From baseline until end
of phototherapy (n=196)
Follow-up after the end
of phototherapy (n=105)
Fig 1 | Schematic representation of planned measurements of patients with psoriasis treated
with ultraviolet B phototherapy. PASI=psoriasis area and severity index; SAPASI=self
administered PASI; EQ-5D=EuroQol questionnaire of health and quality of life outcomes;
SF-6D=scoring algorithm from a subset of questions in the SF-36 health questionnaire;
diary=patients’ diary of frequency and duration of irradiations and frequency of visits to
dermatologist or general practitioner
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that particular cost item. All estimates of costs of work
absence and lost productivity while at work during the




We determined the severity of disease with the psoria-
sis area and severity index (PASI)29 and the self admi-
nistered PASI (SAPASI).30-32 Both scales range from 0
(no lesions) to 72 (extensive erythroderma of the sever-
est degree). Our main outcome measure was the pro-
portion of patients achieving a relevant treatment
effect—that is, a ≥50% reduction in the baseline PASI
or SAPASI (the so called PASI 50 and SAPASI 50).
Other measures were the proportion of patients
achieving a successful treatment effect (≥75% reduc-
tion in baseline disease severity, SAPASI 75 or PASI
75). Treatment safety was assessed by monitoring the
occurrence of acute side effects andmeasuring the total
cumulative dose of ultraviolet B light. We also col-
lected data on demographics, burden of treatment,
patient satisfaction, and preferences.
Cost utility analyses
For the cost utility analyses, we measured health ben-
efit in terms of quality adjusted life years (QALYs)
usingEQ-5Dutilities.33We calculatedQALYs by plot-
ting utilities against time, using the area under the
curve approach.
As an alternative utility measure, we used SF-6D uti-
lities calculated from the short form 36 (SF-36)
questionnaire.34 35 The EQ-5D and SF-6Dutility scores
were measured at baseline (t=0), after 23 irradiations
(t=2), and at the end of phototherapy (t=3) (see fig 1).
For those three assessment points, complete data were
available for 94% (185/196) of the participants.
Because of the study design, however, utility scores
weremissing for all participants at the start of photother-
apy (t=1) and during follow-up (t=4 to t=9). We esti-
mated these missing scores using linear multilevel
models (see web extra) and were able to estimate accu-
rately theutility score frompatients’SAPASI score, sex,
and employment status using the following models:
EQ-5D × 100 = 89.843 − (1.428 × SAPASI)
− 10.339 (only for women) + 8.341 (only when
employed)
SF-6D × 100 = 82.499 − (0.976 × SAPASI) − 7.939
(only for women) + 6.471 (only when employed )
− (0.488 × SAPASI) (only when employed).
If the use of multilevel models was impossible
(because of unknown psoriasis severity), we imputed
single missing utility scores using linear interpolation
between the two known values on either side. Remain-
ingmissing datawere imputedwith the groupmean for
the same assessment point.
Cost effectiveness analyses
For the cost effectiveness analyses,wemeasured health
benefit using an integrated measure of clinical effec-
tiveness and time. For that purpose, we calculated the
number of days that participants experienced a rele-
vant treatment effect (≥50% improvement in baseline
SAPASI, SAPASI 50). The outcome was calculated
using linear interpolation from the SAPASI scores
and the various dates of measurement. Similarly, we
assessed the number of days with a successful treat-
ment effect (≥75% improvement in baseline SAPASI,
SAPASI 75). Any missing data that were needed to
Table 1 | Use of resources by patients with psoriasis treated with ultraviolet B phototherapy and their unit costs (€)
Resource Unit cost (€) Source
Home phototherapy By individual patient Invoice prices home care organisations
(see web extra on bmj.com)
Outpatient phototherapy (per irradiation) 9.13* Hospital data (see web extra)
Consultation with dermatologist (10 minutes) 57.50* Manual for costing23
Consultation with general practitioner 20.20 Manual for costing23
Medication By individual drug Medication guide 200325
Travelling costs (per km) 0.16 Manual for costing23
Parking costs for visits to hospital (per visit) 2.50 Manual for costing23
Parking costs for visits to general practice (per visit) 0.25 Reported directly (trial data)
Absence from paid work (per hour) 0 NA
Reduced productivity while at paid work (per hour) By individual patient† Manual for costing23
Absence from unpaid work (per hour) 0 NA
For scenario analyses
Outpatient phototherapy including cost of consultations of
dermatologist (per year)
1011.67‡ National Health Tariffs Authority43
Consultations with dermatologist (per year) 190.74 Online list tariffs44
Absence from or reduced productivity in paid work (per hour) By individual patient† Manual for costing23
Absence from unpaid work (per hour) 10.00 Going rate for informal labour in theNetherlands in2003
Values presented are unit costs for phototherapy as performed with narrowband ultraviolet B light. All unit costs are based on or adjusted to the
2003 price level.
* Weighted mean price of university hospitals and general hospitals.
† Depending on sex and age.
‡ Weighted mean price for the participating hospitals.
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calculate the number of days with a relevant treatment
effect versus a successful treatment effectwere imputed
with the group mean.
Statistical analysis
All comparisons were performed at the end of photo-
therapy and at one year after the end of phototherapy.
It was not necessary to discount costs and outcomes, as
psoriasis is a chronic recurrent disease and the benefi-
cial effect of phototherapy with ultraviolet B light will
generally not last beyond one year.
Initially, we analysed cost and health benefits sepa-
rately. We calculated mean costs, mean QALYs, and
mean number of days with a relevant treatment effect
with their standard deviations for both treatment
groups. Mean differences between both groups are
presented with their 95% confidence intervals.
After that, we combined differences in total costs
with incremental health benefits: first with differences
in QALYs (cost utility analyses), and then with differ-
ences in number of days with a relevant treatment
effect (cost effectiveness analyses). By dividing the
incremental costs by the incremental health benefits,
we produced Incremental Cost Effectiveness Ratios
(ICERs), yielding estimates of costs per QALY gained
and costs per additional day with a relevant treatment
effect.
We estimated uncertainty around the incremental
cost effectiveness ratios (ICERs) using bootstrapping,
generating 1000 replications of each ratio (replicated
ICERs). For visual conceptualisation, we depicted
these replicated ICERs in a cost effectiveness plane.
Thus, the simultaneous dispersion of costs and effects
could be evaluated, and an inference regarding the
likelihood of one treatment being more cost effective
than the other was possible. To indicate the level of
uncertainty around the point estimates of cost per
QALY, we used the replicated ICERs to produce cost
acceptability curves.36
Eventually we examined the robustness of our results
using sensitivity analyses or rather scenario analyses,
presenting three scenarios. Firstly, we investigated the
scenario whenQALYs were calculated from the SF-6D
utilities instead of the EQ-5D utilities.
Secondly, we examined the scenario in which the
costs of absence from paid work were not considered
negligible. For this scenario, hours of absence at paid
work were estimated from the actual time spent on
phototherapy, adjusted for the participant’s employ-
ment status (full time equivalent). Thus, the hours of
absence frompaidworkwere estimated bymultiplying
the time spent on phototherapy and consultations
(including travel time) with the participants’ full time
equivalent. Subsequently, mean hourly productivity
costs varying with age and sex, and an elasticity of 0.8
were applied.23 The costs of absence fromunpaidwork
were valued at €10 per hour (going rate for informal
labour in the Netherlands in 2003).
Finally, we examined a scenario in which the treat-
ment costs of home phototherapy and those of hospital
based phototherapy were assessed with similar meth-
ods. As described above, the treatment costs of outpa-
tient phototherapy were calculated from the societal
perspective, whereas the treatment costs of home
phototherapy had to be calculated using invoice prices
(payers’ perspective). For this last scenario we there-
fore calculated the treatment costs for both inter-
ventions using invoice prices.
All data were analysed according to the intention to
treat principle20 21 using SPSS 15.0 and Microsoft
Excel.
RESULTS
A total of 196 patients were randomised into two treat-
ment arms of 98 participants each. Mean ages at base-
line were 41.2 and 45.0 years (home versus outpatient
treatment), and two thirds of each group (67%, n = 66)
were men. The mean self administered psoriasis area
and severity index (SAPASI) at baseline was 7.2 and
7.3 respectively. Most of the participants were
employed (74.5% (n = 73) and 70.4% (n = 69)), their
mean full time equivalents were 0.86 and 0.87. Mean
travel distances to hospital and general practice were
8.2 km and 2.2 km for the group assigned to home
phototherapy, versus 11.5 km and 2.2 km for the
Table 2 | Use of resources during trial of ultraviolet B phototherapy for patients with psoriasis. Values are means (standard
deviations)
End of phototherapy* One year after the end of phototherapy*
Home therapy Outpatient therapy Home therapy Outpatient therapy
No of UV irradiations:
At home 33.96 (11.70) 1.73 (8.54) 37.35 (19.62) 4.33 (13.75)
In outpatient department 0.48 (2.61) 26.89 (12.03) 5.04 (12.21) 30.90 (18.96)
No of consultations:
With dermatologist 1.19 (0.99) 1.60 (1.16) 4.12 (3.20) 3.93 (2.39)
With general practitioner 0.25 (0.80) 0.13 (0.43) 0.72 (1.59) 1.00 (4.08)
Medication† — — — —
Reduced productivity while at paid work (hours) 2.09 (8.16) 4.80 (17.83) 2.67 (7.19) 3.39 (8.68)
* 196 patients were followed until the end of phototherapy (t=0 to t=3, mean duration 17.6 weeks), 105 patients were followed until one year after
the end of phototherapy (t=0 to t=9, mean duration 68.4 weeks).
† No details given here because the many different types and combinations of medication that were used make it impossible to report the use of
units of medication.
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group receiving phototherapy in an outpatient depart-
ment. All 196 participants were followed until the end
of the phototherapy, mean duration 17.6 weeks (17.9 v
17.4). The first consecutive 105 patients (54 home ther-
apy, 51 outpatient therapy) continued the trial until
one year after the end of phototherapy. The mean
duration of the entire trial was 68.4 weeks (68.7 v 68.1).
Health outcomes
Clinical study
The results of the clinical study20 indicated that home
ultraviolet B phototherapy and outpatient photother-
apy are at least equally safe and effective. For example,
82% of the patients treated at home and 79% of the
patients treated in hospital achieved ≥50% improve-
ment in baseline SAPASI (SAPASI 50) at the end of
phototherapy (difference 3%, 95% confidence interval
−8.6% to 14.2%), while 70% and 73% had reached the
PASI 50 (difference 3%, −15.7% to 11.1%). For ≥75%
improvement in baseline score, these figures were 69%
versus 59% (SAPASI 75) (difference 10%, −4.0% to
23.6%), and 41% versus 42% (PASI 75) (difference
−1%, −15.6% to 13.6%). Safety, as assessed from the
total cumulative doses of ultraviolet B, was similar for
both groups, and also the occurrence of short term side
effects did not differ.20 Patients treated at home, how-
ever, had a lower burden of treatment and evaluated
their therapy significantlymore positively than patients
treated in an outpatient department (P values ≤0.001).
Waiting time (time between inclusion in trial and start
of phototherapy) for home phototherapy was some-
times considerable, but 73% (63/86) of the patients trea-
ted at home thought the waiting time was acceptable or
not a problem. For the group treated in an outpatient
department, this proportion was 79% (46/58).20
Economic evaluation
By the end of phototherapy (t=3, mean 17.6 weeks)
patients treated at home experienced 0.2960 QALYs
compared with 0.2908 QALYs for patients treated in
an outpatient department, indicating no significant dif-
ference in health benefit (difference 0.0052, −0.0244 to
0.0348). One year after the end of phototherapy (t=9,
mean68.4weeks) these figureswere 1.1528 and1.1261
respectively (difference 0.0267, −0.024 to 0.078).
Health benefits in terms of number of days with a
relevant treatment effect (≥50% improvement) were
42.4 (home therapy) versus 55.3 (outpatient therapy)
by the end of phototherapy. As such, patients treated
at home experienced 12.9 fewer days with a relevant
treatment effect than patients treated in an outpatient
department (95% confidence interval −23.4 to −2.4).
By one year after the end of phototherapy, however,
this difference seemed to be reversed, point estimates
Table 3 | Cumulative mean costs (€) of ultraviolet B phototherapy for patients with psoriasis during trial














Phototherapy 577 275 301 (257 to 346) 672 358 314 (204 to 424)
Consultations with dermatologist 69 92 −23 (−41 to −6) 237 226 11 (−52 to 74)
Consultations with general practitioner 5.0 2.6 2.4 (−1.2 to 6.1) 15 20 −6 (−29 to 18)
Medication 77 95 −18(−53 to 17) 228 261 −33 (−168 to 103)
Subtotal 727 464 263 (199 to 326) 1151 864 287 (50 to 523)
Direct non-medical costs (travel costs)†
For phototherapy 2.9 144 −141(−168to−115) 20 160 −140 (−204 to −75)
For visits to dermatologist 5.3 8.6 −3.3 (−5.4 to −1.1) 21 20 0.36 (−9 to 9)
For visits to general practitioner 0.24 0.12 0.12 (−0.09 to 0.32) 0.55 0.41 0.14 (−0.38 to 0.66)
Subtotal 8.5 153 −144(−171to−117) 42 181 −139 (−211 to −68)
Indirect non-medical costs
Absence from paid work 0 0 NA 0 0 NA
Reducedproductivitywhile atpaidwork 65 135 −70 (−180 to 40) 80 103 −23 (−123 to 76)
Absence from unpaid work 0 0 NA 0 0 NA
Subtotal 65 135 −70 (−180 to 40) 80 103 −23 (−123 to 76)
Total costs 801 752 48 (−78 to 174) 1272 1148 124 (−155 to 403)
Incremental cost effectiveness ratios (ICERs)
Cost per EQ-5D QALY gained 9276/QALY 4646/QALY
Cost per SF-6D QALY gained 7908/QALY 7802/QALY
Costs per day gained with a relevant
treatment effect‡
Dominated strategy 20.50/day with a relevant treatment effect
* 196 patients were followed until the end of phototherapy (t=0 to t=3, mean duration 17.6 weeks), 105 patients were followed until one year after
the end of phototherapy (t=0 to t=9, mean duration 68.4 weeks).
† Travel costs are inclusive of parking costs.
‡ ≥50% improvement in baseline severity of psoriasis.
EQ-5D = EuroQol questionnaire of health and quality of life outcomes. SF-6D = scoring algorithm from a subset of questions in the SF-36 health
questionnaire. QALY = quality adjusted life years.
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being 216.5 days (home therapy) versus 210.4 days
(outpatient therapy) with a relevant treatment effect
(difference 6.1, −41.1 to 53.2). The number of days
with ≥75% improvement (successful treatment effect)
were 23.0 versus 24.6 by the end of phototherapy (dif-
ference−1.6,−9.2 to 6.0) and127.6 versus 111.1 byone
year after the end of phototherapy (difference 16.5,
−27.3 to 60.2).
Costs
Table 2 summarises the mean use of resources by the
end of phototherapy (t=3) and by one year thereafter
(t=9). From unit costs and use of resources, we calcu-
lated the direct and indirect medical and non-medical
costs and combined them into mean overall costs of
both interventions (see table 3).
By the end of phototherapy (t=3) the overall costs
were €801 for home phototherapy and €752 for out-
patient phototherapy (difference €48, €−78 to €174).
By one year after the end of phototherapy (t=9) these
costs had risen to €1272 and €1148 respectively (differ-
ence €124, €−155 to €403).
Cost utility analyses
Although the point estimates presented above are not
significantly different across both groups, they suggest
that home phototherapy might be slightly more bene-
ficial (gain ofQALYs) but also slightlymore expensive.
By the end of phototherapy (t=3) the incremental cost
effectiveness ratio (ICER), which relates increased total
costs to a gain in QALYs, was €9276 per QALY
(€48.24/0.0052 QALY). This indicates that each
QALY gained by switching from outpatient photother-
apy to home phototherapy costs €9276. By one year
after the end of phototherapy (t=9) the ICER was only
€4646perQALY (€124.05/0.0267QALY). Fig 2 repre-
sents the 1000 replicated ICERs for cost per QALY at
one year after the end of phototherapy (t=9) (generated
with the bootstrapping technique), together with the
cost effectiveness threshold line of €20000 per QALY.
Cost acceptability (proportion of replicated ICERs on
the right side of the line) was 76.3%.
Fig 3 shows the cost acceptability curve at one year
after the end of phototherapy (t=9), showing the level
of uncertainty around the point estimates of cost per
QALY. To illustrate, if policymakers are prepared to
pay €20 000 for each QALY gained, then they can be
76.3% sure that home ultraviolet B phototherapy is
cost effective. However, if they are willing to pay
€10 000 or €30 000 per QALY, they can be 66.7% or
79.2% sure that home phototherapy is cost effective.
The results at the end of phototherapy (t=3) indicated
that the likelihood of home phototherapy being cost
effective was 56.9% (€20 000/QALY).
Cost effectiveness analyses
For the cost effectiveness analyses, the point estimates
were not significantly different between the two
groups. By one year after the end of phototherapy
(t=9), home phototherapy seemed slightly more bene-
ficial but also slightlymore expensive. The ICER relat-
ing incremental costs to differences in the number of
days with a relevant treatment effect (≥50% improve-
ment) was €20.50 (€124.05/6.05 days with relevant
effect). This indicates that €20.50 is needed to add
one day with a relevant treatment effect. Fig 4 shows
the 1000 replicated ICERs for cost per additional day
with a relevant treatment effect by one year after the
end of phototherapy (t=9).
At the end of phototherapy (t=3), however, outpati-
ent phototherapy seemed more beneficial while also
saving €3.73 per day with a relevant treatment effect,
indicating that outpatient therapy was the dominant
strategy at this time point.
Scenario analyses
The scenario analysis addressed three areas of subjec-
tivity, two concerning a revised calculation of costs and
one concerning calculation of QALYs.
Firstly, when we assessed utilities using the SF-6D
instead of the EQ-5D, the calculation of QALY gain
and ICERs yielded identical results. The ICERs
totalled €7908 per QALY at the end of phototherapy
(t=3) and €7802 per QALY at one year after the end of
phototherapy (t=9) (see table 3). The likelihood of
home phototherapy being cost effective (cost accept-
ability) was 62.1% and 67.9% respectively.
Secondly, if costs had been calculated based on the
revised assumptions, the total costs for society would
increase for both treatment groups. The increase in
costs for the group treated at home, however, would be
much smaller than the increase in costs for the group
randomised to receive outpatient phototherapy. As a
result, for these scenarios the mean costs for home
phototherapy were lower than the costs for outpatient
phototherapy. Table 4 gives the results of the newly
calculated costs per group. Combined with the gain in
QALYs for the group treated at home, the alternative
calculationof costswouldproducedominated strategies.
DISCUSSION
The results of the clinical study indicated that home




























Difference in mean QALYs
Fig 2 | Incremental costs and QALYs for ultraviolet B
phototherapy at home when compared with phototherapy at
hospital: cost effectiveness plane for incremental costs and
QALYs at one year after the end of phototherapy (entire study
period, 68 weeks), with cost effectiveness threshold line
(€20000/QALY)
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is at least equally effective and safe as office based
phototherapy.20 In the present economic evaluation,
home phototherapy seemed to be slightly more effec-
tive but also slightly more expensive than photother-
apy in an outpatient department. However, both at the
end of phototherapy and at one year thereafter, the
differences between both treatment groups were
mostly small and not significant. The incremental
cost effectiveness ratios (ICERs) remained well below
the generally accepted standard of €20 000 perQALY.
As such, home phototherapy may be regarded a cost
effective intervention.
Key findings
Bothat the endofphototherapy and at one year after the
endofphototherapy, the total costs for homephotother-
apy were slightly higher than the total costs for outpati-
ent treatment. The differences were not significant and
were small (€48/17.6 weeks and €124/68.4 weeks),
especially when the lower burden of treatment and
higher patient satisfaction of home phototherapy are
considered.20
Just as the costs between treatments did not differ sig-
nificantly, neither did the health effects as measured in
QALYs. When both measures were combined, the
ICERs remained far below €20000 per QALY, making
homeultraviolet B treatment a cost effective intervention.
Calculating QALYs and ICERs using the SF-6D instead
of the EQ-5D did not change these conclusions.
The use of more clinical measures of effectiveness
(the number of days with a relevant or successful treat-
ment effect) did add some interesting detail to our
results. The data show that at the end of phototherapy,
the patients treated in an outpatient department had
experienced significantly more days with a relevant
treatment effect (50% improvement). The difference
was 13 days in favour of patients treated in an outpati-
ent department. However, this difference was not
observed for the number of dayswith a successful treat-
ment effect (75% improvement). In addition, at one
year after the end of the phototherapy the difference
was reversed (not significantly), indicating that patients
treated at homemight have a better outcome. Since the
patients treated at home experienced a waiting time of
5.8 weeks on average (compared with 2.2 weeks for
outpatient treatment),20 we conclude that the longer
waiting time for home phototherapy in the Nether-
lands adversely affected the time with relevant reduc-
tion of symptoms. Obviously, in other settings the
waiting time may be different. On the other hand, we
found that most (76%) of the participants thought the
waiting timewas not a problemorwas acceptable.Also
most patients in both groups (92% of those treated at
home and 60%of those treated in an outpatient depart-
ment) stated they would prefer home phototherapy if
they needed ultraviolet B treatment again in the future,
and, most important, home phototherapy was better
appreciated by the patients.20 From the patient’s per-
spective, therefore, the difference in number of days
with a 50% improvement at the end of phototherapy,
although significant, hardly alters the valuation of
treatment. Besides, all other measures of effectiveness
showed no significant differences between the groups.
In the calculation of costs, it should be noted that the
home care organisations were reluctant to submit com-
mercially sensitive information on pricing. We were
therefore unable to calculate the treatment costs for
home phototherapy from a societal perspective but
had to use invoice prices to approximate these costs.
By doing so, we have probably overestimated the costs
of home phototherapy for society. It is plausible to
assume that hadwebeen able to calculate the treatment
costs of home phototherapy from a societal perspec-
tive, homephototherapymight have endedup cheaper
than outpatient phototherapy. To examine the effect of
using invoice prices for home treatment on the overall
costs, we therefore performed a scenario analysis in
which we used invoice prices for outpatient based
phototherapy as well. Themean invoice prices for out-
patient phototherapy were much higher than the costs
estimated for society, and also higher than the mean
invoice prices for home phototherapy. In this scenario
home phototherapy was more effective and cheaper
than phototherapy in an outpatient department—that
is, home therapy would be the dominant treatment
strategy.
Another point to consider is that the results discussed
above were calculated assuming that the costs of
absence at work were negligible. By doing so, we
might have underestimated the total costs of photo-
therapy, especially those of phototherapy in an outpa-
tient setting. The results of the scenario analysis clearly
showed that, by incorporating costs of absence atwork,
the costs of outpatient phototherapy would increase
more than the costs of home phototherapy. This
would make home phototherapy the cheaper option,
again resulting in home therapy becoming the domi-
nant treatment strategy.
Comparison with other studies
To our knowledge, this is the first clinical trial on cost
effectiveness of home phototherapy compared with
outpatient phototherapy for psoriasis. Also no other
economic evaluations comparing home phototherapy


















Incremental costs per QALY (x1000 €)
Fig 3 | Cost acceptability for incremental costs per QALY for
ultraviolet B phototherapy at home when compared with
phototherapy at hospital. Cost acceptability curve at one year
after the end of phototherapy (entire study period, 68 weeks).
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with the standard outpatient phototherapy have been
published, but there are some papers that touch on the
subject. For instance, Yelverton et al37 reported that
home phototherapy with ultraviolet B light was cost
effective. They, however, compared home ultraviolet
B treatment with systemic treatments and with ultra-
violet A combined with a psoralen (PUVA), and did
not perform a cost effectiveness analysis but estimated
the costs of a 30 year treatment period. Since psoriasis
is a chronic disease that is generally treated by a rota-
tion of several different therapies, calculation of the
costs of a 30 year treatment period with just one ther-
apy does not make much sense. Their results do, how-
ever, hint towards home phototherapy being cost
effective for short term treatments. A study by
Cameron16 and several other papers38-41 suggest that
home ultraviolet B phototherapy is likely to be more
cost effective than hospital based phototherapy. A
study of de Rie et al, published in 2001,42 confirms
the accuracy of the range of the costs we calculated
for outpatient ultraviolet B phototherapy.
Strengths and weaknesses of the study
This economic evaluation benefited from being part of
a pragmatic randomised clinical trial. The parallel
group design meant the two interventions were com-
pared throughout the same season, while selection bias
was prevented by randomly assigning participants to
the treatment arms. The pragmatic design ensured that
the two treatments were applied and compared as they
are used in daily practice, hence guaranteeing a good
generalisability of the results. Measurement planning
throughout the study took place according to indivi-
dual clinical landmarks (see fig 1) and did not use
fixed time points starting from baseline. This way of
planning measurements was an advantage for the clin-
ical study because it ensured that both groups could be
compared at clinically comparable moments.
For the cost effectiveness study the applied planning
of measurements had a drawback. Namely, the length
of the waiting time and the length of the treatment per-
iod varied per patient (the latter due to differences in
the number and frequency of irradiations). As a result,
the time until the end of phototherapy was slightly dif-
ferent for the two groups (17.9 weeks for patients trea-
ted at home and 17.4 weeks for those treated in an
outpatient department). Likewise, the mean total
study duration (time until one year after the end of
phototherapy) was slightly different for the groups
(68.1 weeks and 68.7 weeks respectively). This half
week difference in mean study duration might have
given a small overestimation of both the incremental
costs and incremental effects of home phototherapy.
For the cost effectiveness analyses and cost utility ana-
lyses, however, this is likely to have negligible if any
influence, because the overestimation of both values
will disappear when they are combined in an incre-
mental cost effectiveness ratio.
During the one year follow-up after the endof photo-
therapy (t=4 to t=9), we deliberately did not apply cer-
tain questionnaires (see fig 1). This was in order to
reduce the total number and length of the question-
naires per measurement and thereby help maintain
adequate response rates. We chose not to apply ques-
tionnaires to measure health utilities (EQ-5D, SF-6D),
as well as the health and labour questionnaire, theore-
tically making the calculation of QALYs and costs less
accurate. However, we think we have estimated
QALYs accurately using the multilevel linear models
described in the technical appendix (web extra on
bmj.com).Moreover, the uncertainty for the estimated
Table 4 | Scenario analysis of the effects of revised assumptions on mean total costs (€) of ultraviolet B phototherapy for patients with psoriasis
Scenario













A. Outpatient phototherapy costs based on invoice tariffs† 838 1362 −524 (−657 to −392) 1336 1805 −469 (−768 to −169)
B. Costs of absence at paid work estimated from time spent
on therapy, adjusted for employment status‡
1112 1816 −704 (−1053 to −356) 1857 2209 −351 (−973 to 270)
C. A+B 1149 2426 −1277 (−1637 to −917) 1921 2865 −944 (−1608 to −280)
* 196 patients were followed until the end of phototherapy (t=0 to t=3, mean duration 17.6 weeks), 105 patients were followed until one year after the end of phototherapy (t=0 to t=9,
mean duration 68.4 weeks).
† Costs of outpatient phototherapy were based on invoice tariffs rather than based on the real costs for society.
‡ Hours of absence from paid work estimated from actual time spent on therapy (including time for travelling and consultations), adjusted for employment status (that is, full time



























Difference in mean number of days
with a relevant treatment effect
Fig 4 | Incremental costs and number of days with a relevant
treatment effect (≥50% improvement from baseline) for
ultraviolet B phototherapy at home when compared with
phototherapy at hospital: cost effectiveness plane for
incremental costs and incremental number of days with a
relevant treatment effect at one year after the end of
phototherapy (entire study period, 68 weeks)
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costs during the one year follow-up mainly concerns
the productivity costs (due to absence from work or
reduced productivity at work). Our data, however,
indicated that most patients compensated for their
short term absence during normal working hours.
Also a pilot study among 36 patients confirmed that
most patients canminimise costs of productivity losses
by means of flexible arrangements with their employ-
ers. As such, we considered productivity losses to be of
minor importance in determining the total costs for
both treatment arms.
Despite the mentioned limitations, we feel that the
results of our study are unambiguous. Even more, we
think that the results of this study are relevant not only
for patients with psoriasis but for all patients who may
benefit from phototherapy with ultraviolet B light,
such as those with eczema or vitiligo. After all, the
results show that ultraviolet B treatment can just as
well be given at home instead of in an outpatient
department.
Implications for practice and policy makers
Despite the fact theNetherlands is a densely populated
country and distances to the hospital are relatively
small, the results of this economic evaluation unequi-
vocally indicate that home ultraviolet B phototherapy
is a cost effective treatment. Total costs to society for
homephototherapywere similar to those of photother-
apy in outpatient departments, as were the overall
effectiveness and safety of home phototherapy. Con-
sidering the lower burden of treatment and patients’
greater satisfaction with and preference for home
phototherapy, we feel that the positioning of home
phototherapy may be reconsidered and agreed on.
We propose that home ultraviolet B phototherapy
should become the primary treatment option for
patients who are clinically eligible for phototherapy
with ultraviolet B light, and that guidelines should be
adapted to reflect this view. In line with the above, in
countries where reimbursement of home photo-
therapy is not routine practice or is even denied,13 37 39
reimbursement of home phototherapy should be
reconsidered.
In countries where distances to outpatient clinics are
large and where home phototherapy is not common
practice, treatment with ultraviolet B light may not be
available at all for many patients. As a result, patients
may receive traditional systemic drugs or expensive
biological agents only because the infrastructure to
deliver a highly efficacious and cheaper treatment
with ultraviolet B light at home is lacking. Such coun-
tries should investigate how home phototherapy could
be implemented. It is quite likely that introduction of
home therapy would achieve cost savings, especially
compared with use of biological agents.
In our study, the waiting time for home photother-
apy (mean 5.8 weeks)20 affected its effectiveness
adversely, although this was not directly reflected in
patients’ satisfaction with the treatment. Although
most patients felt that the waiting time was
acceptable,20 we think that home care organisations
should be encouraged to reduce the average wait. By
doing so, they can easily improve the treatment’s effec-
tiveness (number of days with a relevant treatment
effect) and will probably increase patient satisfaction
with home treatment even further.
Conclusion
This economic evaluation shows that costs of home
ultraviolet B phototherapy for patients with mild to
severe psoriasis are not higher than those of ultraviolet
B treatment provided in an outpatient department.
Moreover, home phototherapy is cost effective. Since
both treatment strategies are equally effective and safe,
and patients prefer treatment at home, we consider
home phototherapy should be the primary treatment
option for patientswho are clinically eligible for photo-
therapy with ultraviolet B light. Guidelines should be
updated to reflect the results and conclusions of this
trial. In countries where home phototherapy is not
common practice, implementation of this practice
should be investigated. In countries where home
phototherapy is available, provision should be
improved and homephototherapy should be routinely
reimbursed.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Ultraviolet B phototherapy for psoriasis is mostly performed in outpatient departments,
making it time consuming and potentially costly
A recent study showed that ultraviolet B phototherapy provided in patients’ homes is at least
equally effective and safe as outpatient phototherapy, but the burden of treatment is lower
and patients preferred home treatment
WHAT THIS STUDY ADDS
Ultraviolet B phototherapy at home is not more expensive than phototherapy in an outpatient
setting and is a cost effective alternative to outpatient based phototherapy
In countries where home phototherapy is not common practice, implementation of this
practice should be investigated. In countries where home phototherapy is available,
provision should be improved and home phototherapy should be routinely reimbursed.
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